The suppression of apoptosis may contribute to the carcinogenicity of the peroxisome proliferators (PPs), a class of non-genotoxic rodent hepatocarcinogens. Our previous work demonstrated that the PP nafenopin suppressed both spontaneous and transforming growth factor β 1 (TGFβ 1 )-induced hepatocyte apoptosis both in vivo and in vitro. Here, we extend these observations by demonstrating the ability of nafenopin to suppress apoptosis induced by other major candidates for the signalling of cell death in the liver. Treatment of rat or mouse hepatocyte monolayers with TGFβ 1 or the DNA damaging drugs etoposide or hydroxyurea induced high levels of apoptosis. Western blot analysis did not support a role for either p53 or p21 waf1 in etoposide-induced apoptosis in rat hepatocytes. Treatment of mouse hepatocytes with an agonistic anti-Fas antibody also resulted in an induction of high levels of apoptosis. Preaddition and continued exposure to nafenopin suppressed apoptosis induced by all three stimuli. Overall, our studies demonstrate that the ability of nafenopin to protect hepatocytes from apoptosis is not restricted to species or apoptotic stimulus. It is possible, therefore, that the PPs may suppress apoptosis by acting on diverse signalling pathways. However, it seems more likely that nafenopin suppresses hepatocyte apoptosis elicited by each death stimulus by impinging on a core apoptotic mechanism.
Introduction
Non-genotoxic carcinogens have the ability to cause cancer without directly damaging or interacting with cellular DNA (1) . One class of rodent non-genotoxic hepatocarcinogens is the peroxisome proliferators (PPs*). On chronic administration to rodents, PPs cause hepatic peroxisome proliferation, enzyme induction and liver enlargement which is attributed to both hyperplasia and hypertrophy (reviewed in 2,3). Ultimately, chronic exposure of rats and mice to PPs results in the development of liver tumours (4) . Although the peroxisome proliferator activated receptorα (PPARα) is activated by PPs and is thus implicated in their action (5, 6) , the mechanism of action of PPs has not been established at the molecular level.
Sustained hyperplasia may not be sufficient to explain liver *Abbreviations: PP, peroxisome proliferator; TGFβ 1 , transforming growth factor-beta-1; PPARα, peroxisome proliferator activated receptorα; Fas, Fasreceptor; FasL, Fas-ligand; TNF, tumour necrosis factor; DMF, dimethylformamide; PMSF, phenylmethylsulphonyl fluoride; HU, hydroxyurea.
wt changes and tumour development following administration of PPs (7, 8) ; these may result from increased hyperplasia coupled to the suppression of apoptosis (9) (10) (11) . This hypothesis is supported by the observation that the withdrawal of PPs from hyperplastic livers resulted in a decrease in liver wt accompanied by an increase in apoptosis (12, 13) . A role for the suppression of apoptosis was supported by an in vitro study which showed that nafenopin could suppress both spontaneous apoptosis and that induced by transforming growth factor-beta-1 (TGFβ 1 ), a physiological negative growth regulator in the liver (14) . This work was followed by an in vivo study that confirmed this observation (13) . Although, TGFβ 1 plays a major role in regulating liver apoptosis (reviewed in 15) , there are other candidates for the signalling of cell death in the liver. The Fas antigen (also called APO-1 or CD95) is a member of the tumour necrosis factor (TNF) receptor family. The Fas receptor is expressed abundantly in mouse liver tissue (16) and binding of Fas by the Fas ligand (FasL) leads to cell death via apoptosis (reviewed in 17). In addition, binding of Fas by an agonistic anti-Fas antibody has been shown to induce rapid, massive hepatocyte apoptosis both in vivo (18) and in vitro (19) .
In the liver and other tissues, the initiation-promotion model of carcinogenesis is widely accepted (reviewed by 20) . This model suggests that DNA damage may become fixed into the genome by mis-sense/mismatch mutation during DNA synthesis (21) . Surviving DNA-damaged cells may then develop into preneoplastic foci (22) . To model this process in vitro, we used two well-characterized DNA damaging drugs, etoposide and hydroxyurea. Etoposide is a non-intercalating DNA damaging agent which acts by stabilizing the DNAtopoisomerase II complex during DNA replication, resulting in the development of DNA double strand breaks (23, 24) . In contrast, hydroxyurea is an antimetabolite which inhibits the enzyme, ribonucleotide reductase, resulting in single strand breaks of the DNA duplex. The lesions induced by both etoposide and hydroxyurea have been shown to lead to cell death via apoptosis in several cell types including hepatoma cells (14) .
Initially, we hypothesized that nafenopin might suppress apoptosis induced by a specific stimulus, the negative liver growth regulator TGFβ 1 (14) . This hypothesis was based on observations that the PP nafenopin could suppress apoptosis induced by TGFβ 1 , but not that caused by the above mentioned DNA damaging agents in the well differentiated FaO rat hepatoma cell line (14) . To confirm and extend this observation, we wished to examine the ability of nafenopin to suppress apoptosis induced by diverse stimuli in both rat and mouse hepatocytes. DNA-damage induced apoptosis was examined and the involvement in this process of the p53 tumour suppressor protein and its transcriptional target p21 waf1 were explored. Also, given the ability of the Fas signal to destroy the liver in vivo, we determined whether nafenopin could suppress apoptosis induced by the Fas-FasL system.
Materials and methods

Materials
Nafenopin (2-methyl-2-[p-(1,2,3,4-tetrahydro-1-napthyl)-phenoxyl] propionic acid) was a gift from Ciba-Geigy, Switzerland. Native human platelet TGFβ 1 , etoposide and hydroxyurea were purchased from Sigma, UK. Hamster homogenous monoclonal antibody (Jo2 antibody) against mouse Fas was purchased from Pharmingen, USA. CM5 polyclonal p53 primary antibody was a kind gift from Dr Ted Hupp (Dundee University, UK). p21 waf1 primary antibody was a kind gift from Dr Kathryn Ball (Dundee University, UK). Hoescht 33258 was from Molecular Probes Inc., USA. Secondary antibodies were from Dako, UK. The enhanced chemiluminescence (ECL) kit was purchased from Amersham, UK. Foetal calf serum was from Advanced Protein Products, UK. All other tissue culture reagents were purchased from Flow UK, Gibco UK or Sigma UK.
Preparation of primary hepatocytes
Rat and mouse hepatocytes were prepared by collagenase perfusion (25) . Briefly, 180-200 g male (8-10 weeks old) Alderley Park rats (Wistar derived) or 25-35 g male (6-8 weeks old) B6C3F1 mice (Harlan Olac, UK), were subjected to terminal anaesthesia using ether and their livers were perfused with 0.05% w/v collagenase. Digested livers were passed through a 0.125 mm gauze, and the resultant cell suspension was washed and counted using a haemocytometer. Viability was determined by trypan blue exclusion. All cell preparations had a viability of 70-95% on isolation.
Culture of primary hepatocytes
Unless otherwise stated, 2ϫ10 6 freshly isolated hepatocytes were placed in 25-cm 2 flasks in 4 ml of Williams medium supplemented with 10% foetal bovine serum (heat inactivated), 10 µg/ml insulin, 0.1 mM hydrocortisone, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, termed 'complete medium'. Flasks were precoated with rat tail collagen to aid attachment of hepatocytes. Cultures were maintained at 37°C in a humidified atmosphere and the medium was changed at 4, 24 and every subsequent 48 h after seeding.
Treatment of hepatocytes with nafenopin
Nafenopin was added as indicated to the medium of hepatocytes from a ϫ400 stock solution in dimethylformamide (DMF). The final concentration of nafenopin used was 50 µM in all experiments. Control flasks were treated with DMF to the same final concentration of 0.25% (v/v). Treatment of cells with TGFβ 1 , etoposide or HU Hepatocyte monolayers were established as described then maintained for 24 h in complete medium. All flasks were then changed into serum free conditions and maintained for 24 h with or without 50 µM nafenopin. This period in serum-free conditions rendered the hepatocytes more sensitive to the apoptotic stimuli. After this period, TGFβ 1 (5 ng/ml from a 2 µg/ml stock solution in 4 mM HCl, 0.1% BSA), etoposide (40 or 100 µM from a ϫ400 stock in DMF) or HU (4 or 5 mM from a ϫ100 stock in Williams medium) were added to the hepatocytes in the continued presence or absence of nafenopin. Control flasks were treated with the appropriate concentration of solvents. After 24 h, cells were fixed and stained with Hoescht 33258 for evaluation of apoptosis as described below.
Treatment of cells with anti-Fas antibody
Hepatocyte monolayers were established and treated for 24 h with or without nafenopin as described above. After this period, Jo2 anti-Fas antibody (0.5 µg/ml) was added in the continued presence or absence of nafenopin. Control flasks were treated with mouse IgG. After 6 and 24 h, cells were fixed and stained with Hoescht 33258 for evaluation of apoptosis as described below.
Measurement of apoptosis
We have shown previously that apoptotic hepatocytes remain attached to the monolayer and can be detected by Hoescht 33258 staining of condensed chromatin (14, 26) . The monolayers were fixed in ice-cold methanol/acetic acid (3:1) for 5 min. Cells were stained with Hoescht 33258 (5 ng/ml in physiological saline) for 10 min, washed in distilled water and mounted in a solution of 20 mM citric acid, 50 mM disodium orthophosphate and 50% glycerol to achieve optimum fluorescence. Cells were examined at a wavelength of 350-460 nm using an inverted Leica microscope with a far UV fluorescent filter. Apoptotic cells were identified as those with brightly staining, condensed chromatin. Where one apoptotic hepatocyte had generated multiple apoptotic bodies, this was scored as one. A total of 1000 Ϯ 100 cells were counted per flask in 10 random fields. Evaluation of p53 and p21 waf1 protein expression in primary hepatocytes by western blotting Primary hepatocytes (2 x 10 6 cells) were placed in uncoated 25-cm 2 flasks in complete Williams medium for 24 h. All flasks were then changed into serum-300 free conditions and maintained for 24 h. After this period, etoposide (40 µM from a ϫ400 stock in DMF) was added to the hepatocytes. The flasks were then incubated for either 4 or 8 h. The cells were scraped from the flasks and similar treatment groups were pooled together, each treatment group containing 1 x 10 7 cells. The samples were sonicated and centrifuged in EDTA (1 mM)-PBS containing the protease inhibitor phenylmethylsulphonyl fluoride (PMSF). The pellet was discarded and the protein content of the supernatant calculated using the BioRad protein assay.
SDS-polyacrylamide gels were prepared according to the method of Laemmli and Favre (27) . A 40 µg sample of protein was loaded per lane on to either 10% acrylamide gels with 3.5% stacking gels for p53 or to 15% acrylamide gels with 3.5% stacking gels for p21 waf1 . Proteins were blotted onto nitrocellulose membranes and probed using polyclonal anti-p53 antibody or polyclonal antip21 waf1 antibody. Swine anti-rabbit secondary antibodies were used to localize the primary antibody and this was detected using enhanced chemiluminescence. Pure murine p53 protein (a kind gift from Dr Ted Hupp, University of Dundee) was used as a positive control to check the specificity of the p53 antibody. A protein sample from the murine mast cell line (IC.DP) which is known to express p21 waf1 was included as a positive control for the analysis of p21 waf1 in hepatocytes.
Statistical analysis
Analyses were carried out using the GLM procedure in SAS (28) . Differences from control were tested statistically by comparing like groups with or without nafenopin least squares means were compared using a two-sided Student's ttest, based on the error mean square in the analysis. Significance at or greater than the 1% (P ഛ 0.01) or 5% (P ഛ 0.05) level is indicated by * or **, respectively.
Results
We have previously shown that nafenopin suppresses apoptosis in rat hepatocytes induced by TGFβ 1 (14) . The effect of nafenopin was not merely a delay in rodent hepatocyte cell death but a suppression since this chemical confers a survival advantage on hepatocytes for up to 18 months (reviewed in 10). The optimum time point for detecting nafenopin-mediated suppression of apoptosis by all death stimuli tested below was 24 h (data not shown). After 24 h there are few cells remaining in the nafenopin free cultures making a valid comparison of test versus control difficult and, therefore, the 24-h time point was chosen for these studies.
Suppression of TGFβ 1 -induced apoptosis in rat and mouse
Treatment of rat and mouse hepatocyte monolayers with TGFβ 1 (5 ng/ml) for 24 h resulted in the induction of apoptosis (Figures 1c and 2c) . As reported previously (14) , treatment of rat hepatocyte monolayers with TGFβ 1 caused a significant eight-fold increase in the number of apoptotic cells detected (P ഛ 0.01). Treatment of mouse hepatocyte monolayers with TGFβ 1 caused a significant five-fold increase in the number of apoptotic cells detected (P ഛ 0.01). The TGFβ 1 solvent, HCl had no significant effect on cell viability (data not shown). Pre-addition of 50 µM nafenopin to either rat or mouse cultures treated with TGFβ 1 significantly reduced by ജ50% the number of apoptotic cells detected (P ഛ 0.01) (Figures 1c and 2c) . The addition of the nafenopin solvent DMF had no effect on apoptotic cell number (data not shown). Suppression of DNA-damage induced apoptosis in rat and mouse Hydroxyurea (HU) and etoposide induced a concentration dependent increase in the number of apoptotic cells in both rat and mouse hepatocytes (data not shown). In the rat, maximal apoptosis was induced by HU and etoposide at 4 mM and 40 µM, respectively (Figure 1) . The pre-addition of nafenopin to rat hepatocyte monolayers dramatically suppressed this DNA-damage induced apoptosis (P ഛ 0.01) ( Figure 1C ). In the mouse, maximal apoptosis was induced by HU and etoposide at 5 mM and 100 µM, respectively ( Figure Fig. 1. (A) Fluorescent micrograph of a rat hepatocyte monolayer after treatment with etoposide (40 µM) in contrast to etoposide treated rat hepatocytes pretreated with nafenopin (50 µM) (B). (C) Percentage of cells with an apoptotic morphology as detected by Hoescht 33258 staining of primary rat hepatocyte monolayers treated with 5 ng/ml TGFβ 1 , 40 µM etoposide or 4 mM hydroxyurea, with (j) and without (u) 50 µM nafenopin. Data points are the mean of four independent experiments where 1000 Ϯ 100 cells in ten random fields were scored for each condition in each experiment. **P ഛ 0.01, significantly different from appropriate treatment alone.
2). As with the rat hepatocyte system, pre-addition of nafenopin suppressed dramatically the apoptosis induced by etoposide or HU (P ഛ 0.01) ( Figure 2C ). The addition of the etoposide and nafenopin solvent, DMF, had no effect on apoptotic cell number in either the rat or mouse system (data not shown). Expression of p53 and p21 waf1 in primary rat hepatocytes in response to DNA damage Treatment of rat hepatocytes with the DNA damaging agent etoposide (40 µM) led to an increase in apoptosis as stated above. Upon western blot analysis using the CM5 anti-p53 antibody the principal band detected was~53 kd, coinciding with the p53 standard (Figure 3 ). Another band of unknown identity was detected at a higher molecular wt in all of the lanes. P53 protein levels were not influenced by the isolation or plating procedures of the hepatocytes (data not shown). The p53 protein was detected at both 4 and 8 h after etoposide treatment. However, treatment with etoposide did not lead to a detectable increase in p53 protein levels at either 4 or 8 h compared to the untreated controls (Figure 3 ). P21 waf1 protein was not detected in any experiment (n ϭ 3) (data not shown). 
Suppression of apoptosis induced by anti-Fas antibody
Treatment of mouse hepatocytes with Jo2 anti-Fas antibody caused a concentration-dependent induction of apoptosis (data not shown). Incubation of mouse hepatocytes with the optimum concentration of Jo2 anti-Fas antibody (0.5 µg/ml) caused a significant five-fold induction of apoptosis compared with control (P ഛ 0.01) ( Figure 4C ). Pre-addition of 50 µM nafenopin to mouse hepatocyte cultures treated with the agonistic Jo2 anti-Fas antibody significantly reduced by 50 Ϯ 10% the number of apoptotic cells counted (P ഛ 0.01) ( Figure  4C ). IgG alone had no significant effect on mouse hepatocyte apoptosis. The addition of the nafenopin solvent DMF had no effect on apoptotic cell number (data not shown). Treatment of rat hepatocytes with Jo2 anti-Fas antibody failed to induce apoptosis (data not shown).
Discussion
Perturbation of hepatocyte growth control has been implicated as a major contributor to the hepatocarcinogenicity of the PP class of non-genotoxic carcinogens (9, 11, 14, 26) . The hypothesis that the suppression of apoptosis may be important in non-genotoxic carcinogenesis is based on observations made both in vivo and in vitro where nafenopin can suppress spontaneous and TGFβ 1 -induced apoptosis (14, 29, 30) . We observed previously that nafenopin could not suppress DNA 302 damage-induced apoptosis in the well differentiated hepatoma cell line, FaO (14) , suggesting that the suppression of apoptosis by PPs may be specific for spontaneous or TGFβ 1 -induced apoptosis (14) . To confirm and extend this hypothesis, the ability of PPs to suppress apoptosis triggered by other major candidates for signalling of cell death in the liver was examined. To maximize the relevance of our model to rodent carcinogenesis, primary hepatocytes from both rat and mouse were utilized.
Hepatocyte apoptosis can be triggered by many stimuli. However, the perturbation of spontaneous apoptosis may be most relevant to non-genotoxic carcinogenesis. Although termed spontaneous, it is probable that such apoptosis is triggered by DNA damage caused by oxidative damage, replication errors or environmental and dietary genotoxins (reviewed by 31). In the liver, the initiation-promotion model of carcinogenesis is widely accepted (reviewed in 20) wherein DNA is damaged by an initiating carcinogen, irradiation or oxidative stress. Although this damage can be repaired, it may become fixed into the genome by mis-sense/mismatch mutation during DNA synthesis (21) . These DNA damaged cells may then survive resulting in the development of tumours (22) . Since PPs can both suppress apoptosis and induce DNA synthesis, they could accelerate the initiation phase of carcinogenesis by preventing deletion of DNA damaged cells and then promoting their clonal expansion. To evaluate in vitro the hypothesis that nafenopin could suppress apoptosis induced by DNA damage, we employed etoposide and hydroxyurea, agents which we studied in hepatoma cells previously (14) . Nafenopin suppressed DNA-damage induced apoptosis in hepatocytes implying that the tumour suppressor p53 may be one candidate for modulation by nafenopin. p53 has been shown to couple DNA damage to cell cycle arrest and/or apoptosis (32, 33) . p53 Protein was detectable in hepatocyte monolayers, but was not upregulated after treatment with etoposide. Moreover, the p53 transcriptional target p21 waf1 was undetectable and, thus, could not confirm the functionality of hepatocyte p53. Our data do not support an involvement of p53 in etoposide-induced apoptosis in rat hepatocytes, confirming other studies of DNA damage responses in the liver (34, 35) . Based on these results, the abrogation of p53 function in response to nafenopin is most unlikely since no definite role for p53 has been established. Nafenopin also suppressed Fas induced apoptosis. The role of the Fas ligand (FasL)-Fas receptor (Fas) system in normal physiological liver cell death remains to be determined. However, it is clear that Fas is relevant to normal cell death mechanisms in other tissues (17, 36) and is a very potent inducer of liver apoptosis (18, 19) . Fas receptor ligation results in the activation of a caspase cascade (37) (38) (39) and the involvement of this proteolytic cascade in Fas-induced apoptosis has been demonstrated in hepatocytes (40) . TGFβ 1 induced apoptosis (which is attenuated by nafenopin) has also been shown to involve the activation of a caspase cascade (41) and DNA damage also can lead to the cleavage of caspase susbtrates (42) . It is conceivable therefore that nafenopin may impact on one or more of the caspases in order to suppress apoptosis.
In our in vitro model, nafenopin suppresses approximately half of the induced apoptosis irrespective of death stimulus. In vitro, this suppression results in a clear difference in longevity of the hepatocyte cultures. Although it is difficult to translate such in vitro data to the in vivo situation, the suppression of only a small proportion of the spontaneous apoptosis or that triggered by TGFβ 1 , Fas activation or DNA damage could contribute significantly to the fate of the whole organ. It is interesting to note that in vitro nafenopin did not reduce the level of apoptosis to zero in any experiment. In fact, nafenopin only suppresses around 60% of the maximal apoptosis seen. The reason for this is unclear. It is possible that nafenopin suppresses apoptosis of cycling, but not quiescent cells. Other possibilities include the existence of intrinsically nafenopin resistant cells, differential metabolism of nafenopin in vitro compared to in vivo, or the existence of apoptotic stimuli which over-ride the effect of nafenopin. The most likely cause is that the trophic support received by the hepatocytes in vivo is lacking in our in vitro system keeping the basal levels of apoptosis high.
Our studies demonstrate that the ability of nafenopin to protect hepatocytes from apoptosis is not restricted to the apoptotic stimulus applied. In addition, our data support and extend the lack of species difference with respect to both rat and mouse in the suppression of apoptosis by nafenopin (26) . One known signalling pathway is that mediated by the peroxisome proliferator activated receptor α (PPARα) which is activated by PPs (5, 43) . PPs act via PPARα to suppress both spontaneous and TGFβ 1 induced apoptosis (44) . We speculate that activation of the PPARα pathway may lead to the transcription of key genes involved in the suppression of not only TGFβ 1 -induced apoptosis, but also that induced by Fas and DNA damage. Indeed, the lag of 24 h seen prior to an observable effect of nafenopin on apoptosis may reflect the time required for activation of PPARα.
The immediate biochemical consequences of activation of the TGFβ 1 and Fas receptors are well characterized. Similarly, the cell's response to DNA damage with respect to p53 activation is known. Given that nafenopin can suppress apoptosis induced by all three stimuli, two possible mechanisms of action seem possible. Nafenopin could have multiple targets on the distinct biochemical pathways elicited by the three apoptotic stimuli. This seems unlikely. Alternatively, our data point to a mechanism of action for nafenopin which impinges upon core apoptotic machinery, downstream of the convergence point of signals elicited by diverse apoptotic stimuli. The ability of nafenopin to perturb the Bcl-2 family (which functions to determine the threshold at which apoptosis can be engaged) (reviewed in 45) or to inhibit the action of caspases are two possible targets for modulation by nafenopin which are currently under study.
